LISATA THERAPEUTICS, INC. amended Amendment and Waiver with Kuva Labs Inc. and Kuva Acquisition Corp. valued at up to $1.1 million (effective 2026-05-03).
“On May 3, 2026, Lisata Therapeutics, Inc. (the “Company” or “Lisata”) and Kuva Labs Inc., a Delaware corporation (“Parent”), together with Kuva Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent (“Purchaser”), entered into an amendment and waiver (the “Amendment and Waiver”) to the previously announced Agreement and Plan of Merger, dated as of March 6, 2026, by and among Parent, Purchaser and the Company (the “Merger Agreement”).”
Material Agreements
LISATA THERAPEUTICS, INC. entered into Agreement and Plan of Merger with Kuva Labs Inc. (effective 2026-03-06).
“On March 6, 2026, Lisata Therapeutics, Inc., a Delaware corporation (the “Company” or “Lisata”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Kuva Labs Inc., a Delaware corporation (“Parent”), and Kuva Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent (“Purchaser”).”
Material Agreements
LISATA THERAPEUTICS, INC. amended Term Sheet Amendment with Kuva Labs Inc. (effective 2026-02-27).
“On February 27, 2026, Lisata and Kuva entered into an amendment to the Term Sheet (the “Term Sheet Amendment”), whereby the parties agreed to extend the expiration date of the Term Sheet to March 7, 2026.”
Material Agreements
LISATA THERAPEUTICS, INC. entered into Binding Term Sheet with Kuva Labs Inc. valued at $4.00 per share in cash plus two contingent value rights (CVRs) totaling up to $2.00 per share (effective 2026-01-20).
“On January 20, 2026, Lisata Therapeutics, Inc., a Delaware corporation (the “ Company ” or “ Lisata ”), entered into a binding term sheet (the “ Term Sheet ”) with Kuva Labs Inc., a Delaware corporation (“ Kuva ”), pursuant to which Kuva and Lisata agreed to negotiate in good faith and enter into a customary purchase agreement to consummate a negotiated acquisition of Lisata by Kuva (the “ Purchase Agreement ”) whereby Kuva will commence a tender offer to purchase, on a fully-diluted basis, all of the outstanding shares of common stock of Lisata (the “ Shares ”) at a price of $4.00 per Share in cash (the “ Offer ”).”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.